

# Adam Bisaga

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7858494/publications.pdf>

Version: 2024-02-01

77  
papers

3,414  
citations

109264

35  
h-index

143943

57  
g-index

80  
all docs

80  
docs citations

80  
times ranked

3340  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cognitive deficits predict low treatment retention in cocaine dependent patients. <i>Drug and Alcohol Dependence</i> , 2006, 81, 313-322.	1.6	349
2	Development of a Cascade of Care for responding to the opioid epidemic. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 1-10.	1.1	212
3	The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. <i>Psychopharmacology</i> , 2001, 157, 1-10.	1.5	119
4	Cerebral Glucose Metabolism in Women With Panic Disorder. <i>American Journal of Psychiatry</i> , 1998, 155, 1178-1183.	4.0	118
5	Developing an opioid use disorder treatment cascade: A review of quality measures. <i>Journal of Substance Abuse Treatment</i> , 2018, 91, 57-68.	1.5	114
6	Opioid Detoxification and Naltrexone Induction Strategies: Recommendations for Clinical Practice. <i>American Journal of Drug and Alcohol Abuse</i> , 2012, 38, 187-199.	1.1	100
7	Cognition, commitment language, and behavioral change among cocaine-dependent patients.. <i>Psychology of Addictive Behaviors</i> , 2008, 22, 557-562.	1.4	98
8	In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-d-aspartate (NMDA) antagonists. <i>Drug and Alcohol Dependence</i> , 2000, 59, 1-15.	1.6	97
9	Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial. <i>Drug and Alcohol Dependence</i> , 2016, 159, 53-60.	1.6	79
10	The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. <i>Drug and Alcohol Dependence</i> , 2015, 154, 38-45.	1.6	78
11	Interaction between naltrexone and oral THC in heavy marijuana smokers. <i>Psychopharmacology</i> , 2003, 166, 77-85.	1.5	77
12	A randomized placebo-controlled trial of gabapentin for cocaine dependence. <i>Drug and Alcohol Dependence</i> , 2006, 81, 267-274.	1.6	77
13	Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine. <i>American Journal of Psychiatry</i> , 2017, 174, 459-467.	4.0	76
14	Acute effects of memantine in combination with alcohol in moderate drinkers. <i>Psychopharmacology</i> , 2004, 172, 16-24.	1.5	75
15	Acute Interaction of Baclofen in Combination With Alcohol in Heavy Social Drinkers. <i>Alcoholism: Clinical and Experimental Research</i> , 2009, 33, 19-30.	1.4	75
16	Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis. <i>Psychopharmacology</i> , 2020, 237, 2233-2255.	1.5	72
17	Extended-Release Mixed Amphetamine Salts and Topiramate for Cocaine Dependence: A Randomized Controlled Trial. <i>Biological Psychiatry</i> , 2012, 72, 950-956.	0.7	69
18	A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. <i>Addiction</i> , 2013, 108, 1084-1094.	1.7	67

#	ARTICLE	IF	CITATIONS
19	From AIDS to Opioids – How to Combat an Epidemic. <i>New England Journal of Medicine</i> , 2016, 375, 813-815.	13.9	67
20	Reinstatement of Morphine-Conditioned Reward is Blocked by Memantine. <i>Neuropsychopharmacology</i> , 2006, 31, 160-170.	2.8	65
21	A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder. <i>American Journal of Psychiatry</i> , 2019, 176, 129-137.	4.0	62
22	Intermittent Marijuana Use Is Associated with Improved Retention in Naltrexone Treatment for Opiate-Dependence. <i>American Journal on Addictions</i> , 2009, 18, 301-308.	1.3	50
23	Management of relapse in naltrexone maintenance for heroin dependence. <i>Drug and Alcohol Dependence</i> , 2007, 91, 289-292.	1.6	49
24	Antagonism of glutamatergic NMDA and mGluR5 receptors decreases consumption of food in baboon model of binge-eating disorder. <i>European Neuropsychopharmacology</i> , 2008, 18, 794-802.	0.3	48
25	A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period. <i>Drug and Alcohol Dependence</i> , 2010, 111, 97-104.	1.6	48
26	Individual behavioral differences and ethanol consumption in Wistar rats. <i>Physiology and Behavior</i> , 1993, 54, 1125-1131.	1.0	46
27	Effect of glutamate receptor antagonists on N-methyl-D-aspartate- and (S)-1±-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-induced convulsant effects in mice and rats. <i>European Journal of Pharmacology</i> , 1993, 242, 213-220.	1.7	45
28	A review of a national training initiative to increase provider use of MAT to address the opioid epidemic. <i>American Journal on Addictions</i> , 2016, 25, 603-609.	1.3	45
29	The acute effects of gabapentin in combination with alcohol in heavy drinkers. <i>Drug and Alcohol Dependence</i> , 2006, 83, 25-32.	1.6	44
30	RECOGNITION CUE IN THE RAT'S SOCIAL MEMORY PARADIGM. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 1991, 2, 315-327.	0.7	43
31	Therapeutic potential of NMDA receptor antagonists in the treatment of alcohol and substance use disorders. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 2233-2248.	1.9	41
32	Atomoxetine Treatment for Cocaine Abuse and Adult Attention Deficit/Hyperactivity Disorder (ADHD): A Preliminary Open Trial. <i>Journal of Dual Diagnosis</i> , 2009, 5, 41-56.	0.7	39
33	Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies. <i>American Journal on Addictions</i> , 2018, 27, 177-187.	1.3	38
34	Naltrexone treatment for opioid dependence: Does its effectiveness depend on testing the blockade?. <i>Drug and Alcohol Dependence</i> , 2013, 133, 80-85.	1.6	37
35	A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence. <i>Journal of Substance Abuse Treatment</i> , 2014, 46, 546-552.	1.5	37
36	Memantine reduces consumption of highly palatable food in a rat model of binge eating. <i>Amino Acids</i> , 2011, 40, 477-485.	1.2	36

#	ARTICLE	IF	CITATIONS
37	A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. <i>Drug and Alcohol Dependence</i> , 2011, 119, e23-e29.	1.6	35
38	Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial. <i>Drug and Alcohol Dependence</i> , 2018, 187, 171-178.	1.6	35
39	Extended release mixed amphetamine salts and topiramate for cocaine dependence: A randomized clinical replication trial with frequent users. <i>Drug and Alcohol Dependence</i> , 2020, 206, 107700.	1.6	33
40	What should clinicians do as fentanyl replaces heroin?. <i>Addiction</i> , 2019, 114, 782-783.	1.7	32
41	Assessment of riboflavin as a tracer substance: Comparison of a qualitative to a quantitative method of riboflavin measurement. <i>Drug and Alcohol Dependence</i> , 2013, 128, 77-82.	1.6	28
42	Long-Acting Injectable Versus Oral Naltrexone Maintenance Therapy With Psychosocial Intervention for Heroin Dependence. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1371-1378.	1.1	27
43	Antisocial Behavioral Syndromes in Cocaine and Cannabis Dependence. <i>American Journal of Drug and Alcohol Abuse</i> , 2008, 34, 405-414.	1.1	26
44	A Comparison of Independent Depression and Substance-Induced Depression in Cannabis-, Cocaine-, and Opioid-Dependent Treatment Seekers. <i>American Journal on Addictions</i> , 2011, 20, 441-446.	1.3	25
45	Pioglitazone, a PPAR $\gamma$ agonist, reduces nicotine craving in humans, with marginal effects on abuse potential. <i>Pharmacology Biochemistry and Behavior</i> , 2017, 163, 90-100.	1.3	24
46	Utility of lead-in period in cocaine dependence pharmacotherapy trials. <i>Drug and Alcohol Dependence</i> , 2005, 77, 7-11.	1.6	23
47	A randomized, double-blind, placebo-controlled trial of venlafaxine for the treatment of depressed cocaine-dependent patients. <i>American Journal on Addictions</i> , 2014, 23, 68-75.	1.3	22
48	Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone. <i>Drug and Alcohol Dependence</i> , 2015, 147, 122-129.	1.6	22
49	Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders. <i>American Journal on Addictions</i> , 2017, 26, 319-325.	1.3	20
50	COMPARISON OF SERUM FATTY ACID ETHYL ESTERS AND URINARY 5-HYDROXYTRYPTOPHOL AS BIOCHEMICAL MARKERS OF RECENT ETHANOL CONSUMPTION. <i>Alcohol and Alcoholism</i> , 2005, 40, 214-218.	0.9	19
51	Severity of Dependence and Motivation for Treatment. <i>Journal of Addictive Diseases</i> , 2006, 25, 33-41.	0.8	18
52	Effects of alternative reinforcer and craving on the choice to smoke cigarettes in the laboratory. <i>Human Psychopharmacology</i> , 2007, 22, 41-47.	0.7	18
53	Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism. <i>Addiction</i> , 2020, 115, 239-246.	1.7	17
54	Early Abstinence in Cocaine Dependence: Influence of Comorbid Major Depression. <i>American Journal on Addictions</i> , 2007, 16, 283-290.	1.3	16

#	ARTICLE	IF	CITATIONS
55	Betting on change: Modeling transitional probabilities to guide therapy development for opioid dependence.. <i>Psychology of Addictive Behaviors</i> , 2009, 23, 47-55.	1.4	16
56	Contingency Management with pharmacologic treatment for Stimulant Use Disorders: A review. <i>Behaviour Research and Therapy</i> , 2018, 111, 57-63.	1.6	16
57	Quetiapine treatment for cannabis use disorder. <i>Drug and Alcohol Dependence</i> , 2021, 218, 108366.	1.6	16
58	The PPAR $\alpha$ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety. <i>Journal of Psychoactive Drugs</i> , 2018, 50, 390-401.	1.0	15
59	Do withdrawal-like symptoms mediate increased marijuana smoking in individuals treated with venlafaxine-XR?. <i>Drug and Alcohol Dependence</i> , 2014, 144, 42-46.	1.6	14
60	Baseline characteristics of patients predicting suitability for rapid naltrexone induction. <i>American Journal on Addictions</i> , 2015, 24, 258-264.	1.3	13
61	Insula Damage and Quitting Smoking. <i>Science</i> , 2007, 317, 318-319.	6.0	12
62	A novel procedure for assessing the effects of drugs on satiation in baboons: effects of memantine and dexfenfluramine. <i>Psychopharmacology</i> , 2008, 199, 583-592.	1.5	10
63	Brain levels of dextromethorphan and the intensity of opioid withdrawal in mice. <i>Drug and Alcohol Dependence</i> , 2008, 95, 147-151.	1.6	10
64	Comparison of clinical trial recruitment populations: Treatment-seeking characteristics of opioid-, cocaine-, and cannabis-using participants. <i>Journal of Substance Abuse Treatment</i> , 2011, 40, 426-430.	1.5	9
65	&lt;p&gt;Medical Student Attitudes Toward Substance Use Disorders Before and After a Skills-Based Screening, Brief Intervention, and Referral to Treatment (SBIRT) Curriculum&lt;p&gt;. <i>Advances in Medical Education and Practice</i> , 2020, Volume 11, 455-461.	0.7	9
66	Comparison of Substance Use Milestones in Cannabis- and Cocaine-Dependent Patients. <i>Journal of Addictive Diseases</i> , 2012, 31, 60-66.	0.8	8
67	A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder. <i>American Journal of Drug and Alcohol Abuse</i> , 2020, 46, 289-296.	1.1	7
68	Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108482.	1.6	5
69	Delay discounting and neurocognitive correlates among inner city adolescents with and without family history of substance use disorder. <i>Developmental Cognitive Neuroscience</i> , 2021, 48, 100942.	1.9	5
70	Shapes of subcortical structures in adolescents with and without familial history of substance use disorder. <i>Human Brain Mapping</i> , 2022, 43, 2759-2770.	1.9	4
71	Effects of levodopa-carbidopa-entacapone and smoked cocaine on facial affect recognition in cocaine smokers. <i>Journal of Psychopharmacology</i> , 2016, 30, 370-377.	2.0	3
72	Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials. <i>Drug and Alcohol Dependence</i> , 2022, 233, 109343.	1.6	3

#	ARTICLE	IF	CITATIONS
73	Ling <i>et al.</i> "Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder". <i>Addiction</i> , 2015, 110, 875-876.	1.7	2
74	Benzodiazepines and Other Sedatives and Hypnotics. , 2014, , .		1
75	Clinical Studies Using NMDA Receptor Antagonists in Cocaine and Opioid Dependence. , 0, , 261-270.		1
76	Reply to Kunoe (2020) and Ghosh & Singh (2020) regarding Nunes et al . (2020): Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism. <i>Addiction</i> , 2020, 115, 2188-2190.	1.7	0
77	Glutamatergic Agents for Nicotine Dependence. , 2006, , 167-176.		0